What SEC filings does Pliant Therapeutics, Inc. submit to the SEC?

Pliant Therapeutics, Inc. (PLRX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about PLRX?

A Form 4 for PLRX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Pliant Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for PLRX?

The 10-K is Pliant Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all PLRX SEC filings directly on EDGAR?

You can view all historical Pliant Therapeutics, Inc. filings on the SEC EDGAR company page for PLRX. Each filing card on this page links directly to the original SEC document.

How often does Pliant Therapeutics, Inc. file with the SEC?

Pliant Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling PLRX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

PLRX SEC Filing News — Pliant Therapeutics, Inc.

Latest SEC filings for Pliant Therapeutics, Inc. (PLRX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t…

Sector: Healthcare Industry: Biotechnology Market Cap: $55.6M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Pliant Therapeutics, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

PLRX Filing Activity Snapshot 2026-04-17 — 2026-10-02

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Pliant Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 13 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×13: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Raben David (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	575,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Raben David (Chief Medical Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-13

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Iannone Robert (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Iannone Robert (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-13

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Borellini Flavia (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	60,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Borellini Flavia (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

CROWELL GAYLE A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: CROWELL GAYLE A (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

MCCOURT Thomas A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: MCCOURT Thomas A (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Krognes Steve E. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Krognes Steve E. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Curnutte John T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Curnutte John T (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Huh Hoyoung (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Huh Hoyoung (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Cline Darren S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	70,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Cline Darren S (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-17

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Kuo Minnie (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	150,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	150,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	40,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	40,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	55,200	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	55,200	—	—

Filing: Form 4 (Insider Transaction) Insider: Kuo Minnie (Chief Operating Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-17

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Cummings Keith Lamont (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	76,047	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	76,047	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	18,198	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	18,198	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	74,250	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	74,250	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	124,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	124,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	76,200	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	76,200	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	110,500	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	110,500	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	113,300	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	113,300	—	—

Filing: Form 4 (Insider Transaction) Insider: Cummings Keith Lamont (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-17

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Coulie Bernard (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	146,841	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	146,841	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	327,262	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	327,262	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	250,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	250,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	440,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	440,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	206,300	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	206,300	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	256,300	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	256,300	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	325,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	325,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Coulie Bernard (Director, President and CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-17

PLRX insider Form 4 filed for equity award, exercise, or tax withholding

Cheung Lily (Chief Human Resource Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	123,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	123,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	52,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	52,000	—	—
`D`	Disposition to issuer derivative · Stock Option (Right to Buy)	51,750	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	51,750	—	—

Filing: Form 4 (Insider Transaction) Insider: Cheung Lily (Chief Human Resource Officer)

View on SEC EDGAR → Open Filing Document →

Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Pliant Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-11

PLRX filed 8-K — material company event

PLIANT THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-13

PLRX filed 8-K — material company event

PLIANT THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-11

PLRX filed 8-K — material company event

PLIANT THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-11

PLRX filed 8-K — material company event

PLIANT THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-17

PLRX filed 8-K — material company event

PLIANT THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 quarterly reports (10-Q) for Pliant Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-11

PLRX filed Quarterly Report (10-Q)

PLIANT THERAPEUTICS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-11

PLRX filed Quarterly Report (10-Q)

PLIANT THERAPEUTICS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Pliant Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PLRX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PLRX SEC Filings

More Tools for PLRX

PLRX Full Stock Analysis PLRX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PLRX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PLRX stock analysis page.

PLRX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer